PET/CT is a commonly used modality in cancer imaging, as it can help in diagnosis, staging and assessment of treatment response in many cancer types. A better understanding of the tumor microenvironment and identification of multiple selective targets are promoting further investigation into different radiotracers for diagnosis and therapy. In the past few decades many radiopharmaceuticals have emerged for specific oncologic indications providing superior detection rate than some morphologic modalities. The purpose of this review is to provide an update on the most current radiopharmaceuticals used in cancer imaging including the mechanism of action, indications and pitfalls.
Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications.
Keywords: PET/CT (Positron Emission Tomography/Computed Tomography), Radiopharmaceutical, Oncology, Radiotracers